Ms. Jean Hoffman

• 
  www.biospace.com/news_story.aspx?NewsEntityId=112421&So - [Cached Version]
  Published on: 10/8/2008    Last Visited: 10/9/2008  

  Increased availability of generic veterinary medications will enhance the ability of pet owners, who pay out of pocket, to provide their pets with the health care they need," says Jean Hoffman, founder and CEO of Putney, Inc.
  
  Hoffman's comment refers to two studies.Business Week recently reported that purchasing related to domestic companion animals, currently at $41B annually, is the second largest growing category of consumer spending.In a survey by Fleischman Hillard International Communications, fifty per cent of respondents say that a recession would not affect their pet spending.Putney's own focus groups have revealed that veterinarians are open to new generics; especially alternatives to pricey, chronic treatments.
  
  Hoffman, an entrepreneur whose last enterprise, Newport Strategies, sold to Thomson Corporation in 2004, founded Putney to make pet healthcare more affordable and accessible -- a need she recognized when caring for her own aging cats."Pets are cherished family members, yet many, including older pets that need medicines for chronic conditions, are not receiving the full dosage of their veterinarian prescribed medicines due to the high costs of pet pharmaceuticals," she says.Most human pharma products have a generic equivalent available when the patent expires, while 86% of companion animal drugs still have no generic equivalent available years beyond patent expiration.
  
  Hoffman also cites the recently passed Animal Generic Drug User Fee Act as more cause for celebration.

• 
  www.masshightech.com/stories/2008/10/13/weekly13-Maine- - [Cached Version]
  Published on: 10/17/2008    Last Visited: 10/21/2008  

  Jean Hoffman is the founder and CEO the 2-year-old company and, of course, a major pet lover. But she doesn't just bring a love for animals to the job — Hoffman spent her entire career in bulk-pharmaceutical manufacturing and generic drug-focused companies.
  
  In 1990 Hoffman founded Newport Strategies LLC, a consulting firm to the generics industry, which was later bought by Thomson-Reuters Corp. in 2004. Soon after, she started another generics consulting firm called Q Street Advisors.
  
  The idea of starting a generics development company for pets originally came to Hoffman when Dude, her adopted cat, developed hyperthyroidism, a common condition in older cats. The medication that Dude needed was not available in generic form and cost $30 a month. Later, the dosage doubled, as did the cost.
  
  "The concept of needing generic products for pets just stuck in my mind. Not everyone can afford spending $60 a month for their pets," Hoffman said.
  
  To maximize the company's development efforts, Hoffman used the analytical research tools and algorithms developed at Newport Strategies to identify drugs with the highest potential for profitability.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/w - [Cached Version]
  Published on: 10/8/2008    Last Visited: 10/8/2008  

  Increased availability of generic veterinary medications will enhance the ability of pet owners, who pay out of pocket, to provide their pets with the health care they need," says Jean Hoffman, founder and CEO of Putney, Inc.Hoffman's comment refers to two studies.Business Week recently reported that purchasing related to domestic companion animals, currently at $41B annually, is the second largest growing category of consumer spending.In a survey by Fleischman Hillard International Communications, fifty per cent of respondents say that a recession would not affect their pet spending.Putney's own focus groups have revealed that veterinarians are open to new generics; especially alternatives to pricey, chronic treatments.Hoffman, an entrepreneur whose last enterprise, Newport Strategies, sold to Thomson Corporation in 2004, founded Putney to make pet healthcare more affordable and accessible -- a need she recognized when caring for her own aging cats."Pets are cherished family members, yet many, including older pets that need medicines for chronic conditions, are not receiving the full dosage of their veterinarian prescribed medicines due to the high costs of pet pharmaceuticals," she says.Most human pharma products have a generic equivalent available when the patent expires, while 86% of companion animal drugs still have no generic equivalent available years beyond patent expiration.Hoffman also cites the recently passed Animal Generic Drug User Fee Act as more cause for celebration.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 8/14/2008    Last Visited: 8/19/2008  

  Jean Hoffman, CEO of Putney, a GADA member company, commented "The AGDUFA legislation marks the beginning of a new era for animal health.

• 
  tcprod.thomson.com/common/view_news_release.jsp?body_in - [Cached Version]
  Published on: 9/27/2003    Last Visited: 5/3/2004  

  Current Newport CEO and Founder, Jean Hoffman, expressed similar enthusiasm saying, "We have great confidence that Newport's capabilities and intelligence combined with the Thomson global reach and leadership in the pharmaceutical industry will bring great benefit to our customers."

• 
  www.vantulleken.com/newsitem30.aspx - [Cached Version]
  Published on: 4/1/2004    Last Visited: 11/12/2007  

  Current Newport CEO and Founder, Jean Hoffman, expressed similar enthusiasm saying, "we have great confidence that Newport's capabilities and intelligence combined with the Thomson global reach and leadership in the pharmaceutical industry will bring great benefit to our customers."

• 
  7th Annual Generic Drugs Summit - Agenda - Day One - [Cached Version]
  Published on: 8/11/2004    Last Visited: 6/15/2006  

  Jean Hoffman, President, Q STREET ADVISORS, INC.& PUTNEY, INC.

• 
  Biobn - Bio Business Networks - Thursday May 08 2003 - [Cached Version]
  Published on: 4/8/2003    Last Visited: 5/8/2003  

  "Vision CI builds on our decade-long leadership in the area of competitive intelligence for launched products," said Jean Hoffman, President and CEO of Newport."With the pharmaceutical industry facing one of its most challenging times, maximizing the lifetime and revenues from launched products is of paramount importance to every company."
  
  "Vision CI answers the industry's need for high quality and reliable early warning of generic competition.The system offers lifecycle planners and managers, legal and intelligence professionals with an unparalleled global view of upcoming competition for their products.It enhances overall productivity, helping them focus on planning for, and responding to issues rather than researching data," continued Hoffman.

• 
  C&EN: COVER STORY - GENERIC TIDE IS RISING - [Cached Version]
  Published on: 9/8/2004    Last Visited: 8/10/2005  

  In the past, generic companies simply waited for agents of API manufacturers to call with product lists, notes Jean Hoffman, president and CEO of Newport Strategies, a Portland, Maine-based company that analyzes technical intelligence related to generic drug development, manufacture, and marketing.Now that generic companies are focused on challenging patents, they need sophisticated API manufacturers with whom they can partner, she tells C&EN.The generic company's relationship with an API supplier is becoming more like that of an innovator's, she says.
  
  When a generic company is trying to circumvent a patent, how fast the API manufacturer can develop an alternative non-patent-infringing process is critical to the generic company's success in gaining first approval, Hoffman explains.But it's not just about technology, she adds.

• 
  C&EN: COVER STORY - GENERIC TIDE IS RISING - [Cached Version]
  Published on: 9/24/2002    Last Visited: 9/24/2002  

  In the past, generic companies simply waited for agents of API manufacturers to call with product lists, notes Jean Hoffman, president and CEO of Newport Strategies, a Portland, Maine-based company that analyzes technical intelligence related to generic drug development, manufacture, and marketing.Now that generic companies are focused on challenging patents, they need sophisticated API manufacturers with whom they can partner, she tells C&EN.The generic company's relationship with an API supplier is becoming more like that of an innovator's, she says.
  
  When a generic company is trying to circumvent a patent, how fast the API manufacturer can develop an alternative non-patent-infringing process is critical to the generic company's success in gaining first approval, Hoffman explains.But it's not just about technology, she adds.It's also about the API manufacturer's competitiveness, regulatory history, and manufacturing capabilities; what other products it manufactures; and whether it can provide the API in the specific way the generic company demands.

Page:  1 2 3